PMID- 33547948
OWN - NLM
STAT- MEDLINE
DCOM- 20210709
LR  - 20240402
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Print)
IS  - 0171-5216 (Linking)
VI  - 147
IP  - 8
DP  - 2021 Aug
TI  - Detection of circulating genetically abnormal cells using 4-color fluorescence in 
      situ hybridization for the early detection of lung cancer.
PG  - 2397-2405
LID - 10.1007/s00432-021-03517-6 [doi]
AB  - PURPOSE: Available biomarkers lack sensitivity for an early lung cancer. 
      Circulating genetically abnormal cells (CACs) occur early in tumorigenesis. To 
      determine the diagnostic value of CACs in blood detected by 4-color fluorescence 
      in situ hybridization (FISH) for lung cancer. METHODS: This was a prospective 
      study of patients with pulmonary nodules </= 30 mm detected between 10/2019 and 
      01/2020 at four tertiary hospitals in China. All patients underwent a 
      pathological examination of lung nodules found by imaging and were grouped as 
      malignant and benign. CACs were detected by 4-color FISH. Patients were divided 
      into the training and validation cohorts. Receiver operating characteristics 
      analysis was used to analyze the diagnosis value of CACs. RESULTS: A total of 205 
      participants were enrolled. Using a cut-off value of >/= 3, blood CACs achieved 
      areas under the curve (AUCs) of 0.887, 0.823, and 0.823 for lung cancer in the 
      training and validation cohorts, and all patients, respectively. CACs had high 
      diagnostic values across all tumor sizes and imaging lesion types. CACs were 
      decreased after surgery (median, 4 vs. 1, P < 0.001) in the validation set. The 
      CAC status between blood and tissues was highly consistent (kappa = 0.909, 
      P < 0.001). The AUC of CAC (0.823) was higher than that of CEA (0.478), SCC 
      (0.516), NSE (0.506), ProGRP (0.519), and CYFRA21-1 (0.535) (all P < 0.001). 
      CONCLUSION: CACs might have a high value for the early diagnosis of lung cancer. 
      These findings might need to be validated in future studies. Evidence suggested 
      homology in genetic aberrations between the CACs and the tumor cells.
FAU - Feng, Mingxiang
AU  - Feng M
AD  - Division of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Ye, Xin
AU  - Ye X
AD  - Zhuhai Sanmed Biotech. Ltd, Zhuhai, China.
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hongkong and Macao, Zhuhai, 
      China.
AD  - Department of Thoracic surgery, Respiratory Center of Suining Central Hospital, 
      An Affiliated Hospital of Chongqing Medical University, An Affiliated Hospital of 
      North Sichuan Medical College, Suining, Sichuan, China.
FAU - Chen, Baishen
AU  - Chen B
AD  - Department of Thoracic Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen 
      University, Guangzhou, China.
FAU - Zhang, Juncheng
AU  - Zhang J
AD  - Zhuhai Sanmed Biotech. Ltd, Zhuhai, China.
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hongkong and Macao, Zhuhai, 
      China.
FAU - Lin, Miao
AU  - Lin M
AD  - Division of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Zhou, Haining
AU  - Zhou H
AD  - Department of Thoracic surgery, Respiratory Center of Suining Central Hospital, 
      An Affiliated Hospital of Chongqing Medical University, An Affiliated Hospital of 
      North Sichuan Medical College, Suining, Sichuan, China.
FAU - Huang, Meng
AU  - Huang M
AD  - Zhuhai Sanmed Biotech. Ltd, Zhuhai, China.
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hongkong and Macao, Zhuhai, 
      China.
FAU - Chen, Yanci
AU  - Chen Y
AD  - Zhuhai Sanmed Biotech. Ltd, Zhuhai, China.
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hongkong and Macao, Zhuhai, 
      China.
FAU - Zhu, Yunhe
AU  - Zhu Y
AD  - Department of Thoracic surgery, Respiratory Center of Suining Central Hospital, 
      An Affiliated Hospital of Chongqing Medical University, An Affiliated Hospital of 
      North Sichuan Medical College, Suining, Sichuan, China.
FAU - Xiao, Botao
AU  - Xiao B
AD  - School of Biology and Biological Engineering, South China University of 
      Technology, Guangzhou, China.
FAU - Huang, Chuoji
AU  - Huang C
AD  - Zhuhai Sanmed Biotech. Ltd, Zhuhai, China. huang.chuoji@sanmedbio.com.
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hongkong and Macao, Zhuhai, 
      China. huang.chuoji@sanmedbio.com.
FAU - Katz, Ruth L
AU  - Katz RL
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Bai, Chunxue
AU  - Bai C
AUID- ORCID: 0000-0002-3370-5002
AD  - Division of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China. cxbai@fudan.edu.cn.
LA  - eng
GR  - 2019ZT08Y297/The program for Guangdong Introducing Innovative and Entrepreneurial 
      Teams/
PT  - Journal Article
PT  - Multicenter Study
PT  - Validation Study
DEP - 20210206
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Fluorescent Dyes)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/analysis/blood
MH  - Carcinoma, Non-Small-Cell Lung/blood/*diagnosis/surgery
MH  - Early Detection of Cancer/*methods
MH  - Female
MH  - Fluorescent Dyes/analysis
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Lung Neoplasms/blood/*diagnosis/surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplastic Cells, Circulating/*pathology
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Sensitivity and Specificity
PMC - PMC8236478
OTO - NOTNLM
OT  - Circulating genetically abnormal cells
OT  - Early detection of cancer
OT  - Early diagnosis
OT  - Fluorescence in situ hybridization
OT  - Non-small cell lung cancer
COIS- The authors declare that they have no competing interests.
EDAT- 2021/02/07 06:00
MHDA- 2021/07/10 06:00
PMCR- 2021/02/06
CRDT- 2021/02/06 12:07
PHST- 2020/10/26 00:00 [received]
PHST- 2021/01/10 00:00 [accepted]
PHST- 2021/02/07 06:00 [pubmed]
PHST- 2021/07/10 06:00 [medline]
PHST- 2021/02/06 12:07 [entrez]
PHST- 2021/02/06 00:00 [pmc-release]
AID - 10.1007/s00432-021-03517-6 [pii]
AID - 3517 [pii]
AID - 10.1007/s00432-021-03517-6 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2021 Aug;147(8):2397-2405. doi: 
      10.1007/s00432-021-03517-6. Epub 2021 Feb 6.